Welcome to FMTVDM
the Next FRONTIER - Defining PRECISION WITH PURPOSE.
Where Data Meets Diplomacy.
Explore the World of FMTVDM and ITIRD.
About FMTVDM FRONTIER
Our Mission
Opportunity Overview
Whole-Body PET and SPECT systems overcome the field-of-view, speed, and sensitivity limitations of conventional scanners. When coupled with FMTVDM®’s absolute quantification technology, these platforms deliver reproducible, non-invasive measurements of tissue perfusion and metabolic rates—metrics that define the spectrum of health and disease. This capability enables earlier diagnoses, more precise treatment decisions, and scalable screening programs that save lives and resources.
Strategic Benefits
-
Early detection and staging of oncologic, cardiovascular, infectious, and inflammatory diseases
-
Objective treatment monitoring through absolute uptake values
-
Data-driven protocols for population-level screening and resource allocation
-
Alignment with global molecular imaging standards to attract research collaborations
-
Enhanced national prestige as a leader in cutting-edge healthcare technology
Performance Comparison
Implementation Roadmap
-
Technical Briefing Convene your leadership, clinical experts, and biomedical engineers for an in-depth review of system architecture and validation data.
-
Pilot Deployment Launch a focused clinical study at a major referral center to demonstrate diagnostic accuracy, workflow integration, and cost-benefit metrics.
-
Scale-Up & Training Expand to regional hospitals, train technologists and physicians in FMTVDM® protocols, and establish a national registry for outcomes tracking.
Exclusive Partnership: Select Nation Status (SNS)
The FMTVDM® Consortium will award Select Nation Status (SNS) to three early adopters, granting exclusive national usage rights through 1 January 2030. SNS partners gain priority access to software updates, training grants, and collaborative research funding—solidifying a decade-long competitive edge.
🍀 Cloverleaf as a Symbolic Emblem
The Cloverleaf represents unity, differentiation, and
strategic precision.
Cloverleaf vs Rosetta Stone
-
Cloverleaf = Differentiation, precision, and metabolic truth
-
Rosetta Stone = Translation, unlocking meaning across systems
🍀 Cloverleaf Motif
Definition: A four-lobed emblem representing the convergence of strategic pillars—each leaf symbolizing a distinct but interdependent domain of impact.
Symbolic Interpretation:
Visual Identity:
-
Symmetry = Balance and unity across domains
-
Differentiation = Each leaf is distinct, yet harmonized
-
Centerpoint = FMTVDM FRONTIER as the nucleus of transformation
The Cloverleaf is not just a motif—it’s a map. A visual declaration of FMTVDM FRONTIER'S multidimensional mission.
🎯 Precision with Purpose
Definition: A disciplined commitment to exactness—where every measurement, decision, and symbol serves a deliberate, mission-driven function. It is not merely accuracy for its own sake, but accuracy that advances a higher goal: clinical truth, diplomatic resonance, and global impact.
In the context of FMTVDM FRONTIER:
-
Precision = Absolute quantification of metabolic signals
-
Purpose = Transforming diagnostics, elevating health systems, and reinforcing sovereign capability
“Precision with Purpose” is the ethos behind FMTVDM FRONTIER—where data is not just measured, but made meaningful.
🧭 Strategic Briefing: FMTVDM & Select Nation Status
Reframing Global Leadership Through Clinical Precision
🔹 Global Cooperation: The Diplomatic Vehicle
“Cooperation is the scaffolding—equity is the architecture.”
-
FMTVDM FRONTIER enables cross-border alignment on imaging standards, clinical protocols, and data integrity.
-
Select Nation Status invites collaborative legitimacy, not imposed hierarchy.
-
Ministries and scientific bodies become co-authors of precision, not recipients of charity.
🔹 Global Access: The Strategic Outcome
“Global access is no longer a handout—it is earned through precision.”
-
FMTVDM FRONTIER redefines eligibility for care, regardless of GDP or geopolitical status.
-
Select Nation Status elevates all Nations including non-G7 nations to leadership roles in healthcare innovation.
-
Scientific legitimacy becomes a currency of influence, reshaping diplomatic norms.
🔹 Narrative Positioning
-
FMTVDM FRONTIER is the Rosetta Stone and Cloverleaf of clinical truth—translating metabolic signals into actionable data.
-
Select Nation Status is the passport to equity—granted through evidence, not politics.
-
“Precision with Purpose” is not a slogan—it’s a strategic doctrine.
🧭 Strategic Overlay:
Global Cooperation → Enabler
Global Access → Outcome
🔬 In the Context of FMTVDM FRONTIER
FMTVDM FRONTIER doesn’t just diagnose—it redefines the need for further care, as well as measuring which treatment(s) work and which do not.
Global Cooperation is what allows ministries, scientific bodies, and heads of state to align on clinical protocols, imaging standards, and data-sharing agreements. It’s the diplomatic scaffolding.
Global Equal access, however, is the result FMTVDM FRONTIER is driving toward:
-
Equal access to FMTVDM FRONTIER technology
-
Standardized diagnostic precision and theranostic measurement across resource-diverse nations
-
Empowerment of all Nations including non-G7 nations to lead in healthcare innovation
🏛️ In the Context of Select Nation Status
“Equal access is no longer a handout—it is earned through precision.”
Global Cooperation is how you build the coalition—through strategic briefings, modular overlays, and shared clinical language.
Equal Global access is also a paradigm shift:
-
Nations previously sidelined now become clinical and diplomatic leaders
-
Scientific legitimacy becomes a currency of influence, not just GDP
-
Equity is no longer a handout—it’s a recalibration of global leadership
🧠 Narrative Framing
-
FMTVDM FRONTIER is not just offering a tool.
-
FMTVDM FRONTIER is a new metric for global legitimacy.
-
FMTVDM FRONTIER becomes the Rosetta Stone and Cloverleaf for clinical truth.
-
Select Nation Status becomes the passport to equity—earned through precision, not politics.
Our Team
Richard M. Fleming, PhD, MD, JD
Education & Training
• PhD in Physics – Completed advanced doctoral-level work in physics, focusing on plasma and positron annihilation studies.
• MD – University of Iowa College of Medicine, graduated with high honors and selected as one of 17 Honors Students.
• JD – Earned a law doctorate, receiving recognition for legal research and memorandum of law writing.
• Masters Studies Experimental Psychology.
• Bachelor’s of Science and Bachelor's of Arts: Biology and Psychology with Chemistry minor.
• Specialty Training – Internal medicine, cardiology, and nuclear medicine, with specialized certification in PET imaging.
Scientific Contributions
• Unified Theory of Inflammation (1994) – Proposed that inflammation, blood clotting and immunologic response is the root cause of cardiovascular disease and other chronic illnesses including; but not limited to, cancer and infectious diseases. Aka. InflammoThrombotic Immunologic Response (ITIR) Disease (ITIRD) Theory.
• FMTVDM© (Fleming Method for Tissue and Vascular Differentiation and Metabolism, US Patent #9,566,037; 2017) – A quantitative nuclear imaging method measuring both blood flow and metabolism to improve accuracy in diagnosing and monitoring heart disease, cancer, and infectious diseases.
• Publications & Presentations – Published in peer-reviewed journals, presented at scientific societies such as AHA, ACC, ASNC and SNMMI, and featured on ABC’s 20/20.
COVID-19 Research
• Has published approximately 500 peer reviewed papers, 12 medical textbook chapters, 27 books and Editor-in-Chief of a Cardiology Textbook.
• Began research in 2020 on SARS-CoV-2, identifying it as man-made. • Conducted early treatment studies and vaccine investigations, including analysis of blood-vaccine interactions (2021) and analysis of DNA and mRNA within the genetic vaccines.
• Applied FMTVDM© to evaluate COVID-19 impacts and potential therapies.
Legal and Advocacy Work
• Using his JD, Dr. Fleming has engaged in civil rights and medical freedom advocacy, particularly related to public health policy and bodily autonomy.
Recognition & Media
• Known for challenging conventional cholesterol-based models of heart disease with his inflammation theory.
• Appeared in documentaries, interviews, and podcasts discussing medicine, law, and policy.
• Maintains an active presence through The Fleming Method and FMTVDM websites, providing access to his research and educational materials.
Peer-Reviewed Data
• Dr. Richard M. Fleming’s CV (available upon request).
Nash Singh & Nisha Devkurran
Public Relations and Marketing
Since 2013, Nash and Nisha have conceptualized and hosted ground-breaking conferences and author tours across the following demographics: USA – New York, Los Angeles, San Francisco, Fort Myers, Phoenix, Chicago, Minneapolis, Houston, Dallas, Heber City Utah, New Jersey · Australia – Melbourne, Sydney, Perth, Brisbane · New Zealand – Auckland · South Africa – Johannesburg and Cape Town.
Their vision is to help charter new courses for humanity through the dissemination of critical information, inspiring dialogue, action, and positive change in the world. The international list of thought leaders they have worked with include New York Times bestselling authors, celebrities, scientists, researchers, and academics from fields including medicine, ethnobotany, archaeology, political science, law, anthropology, investigative journalism, and global geopolitics.
Nash’s prior experience as automotive industry marketing director expresses through nationwide media and marketing campaigns across a diverse range of demographics, while Nisha’s legal and finance director expertise ensures integrity, professionalism, and dynamic outcomes. Their work in the international events industry enables access to some of the largest media conglomerates on multiple continents, and a network of professionals in varying professional fields.
Their recent achievements include a 10-city conference tour with Dr. Richard M. Fleming PhD, MD, JD in 2022. Please direct media and public relations communications to Nash and Nisha through the Contact FMTVDM FRONTIER email noted below.
James Lawrence Gagan II
Operations & Technical Resources
Educational Background
• Attended Butler University, pursuing both a BA in Business Administration and a BA in Economics.
• Life and Health Insurance License
• Series 7 license, Stock Broker license
• Series 63 Uniform Securities Agent State Law license
• Certified Novell Network Engineer (CNE)
• Microsoft Certified MCSE
• Cisco Certified CNA
• Coldfusion Certified Developer
Professional Background
• Think Tank Software Development Corp.: Founded the company in 1990, served as the President of this company, which specialized in software development for 25 years.
• Think Tank Networking Technology Group: Founder, provided comprehensive computer consulting services, data center design, and managed services for Government, Education, and Corporate clients.
• SBA Young Entrepreneur of the Year for Indiana in 1993.
• Think Tank Cellular: Co-Founder of Verizon Cellular Stores, focused on government and corporate accounts.
• MinkeySoft LLC: Founder and CEO, creator of software platforms including MySchoolDance.com and ThinkHelpdesk.com.
• Banshee Holdings, LLC: Managing Partner for this property management company.
• Saxon Oil Company Ltd.: Served on the board of this company.
• Direct Buy of South Lake: Partner for this franchise.
• Holds a Universal US Patent No: US8800461B2 - Boat Separator Device
Matthew Fleming, BS, BA, NRP, FP-C
Graduate from the University of Northern Iowa (UNI) – 2017
-
Bachelor’s of Science (B.S.) in Physics
-
Bachelor’s of Arts (B.A.) in Biochemistry
-
Bachelor’s of Arts (B.A.) in Biology
UCLA Paramedic Program Graduate from the David Geffen School of Medicine at UCLA - Center for Prehospital Care – 2018
-
Associate’s of Science (A.S.) in Paramedicine (UCLA Paramedic Program/West Los Angeles College)
Paramedic National Registry through the National Registry of Emergency Medical Technicians (NREMT) - 2018
Creighton University Critical Care Paramedic Program Graduate – 2019
Flight Paramedic Board Certification through the International Board of Specialty Certification (IBSC) - 2020